Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


Denali Therapeutics To Present Interim Data Phase 1/2 Study Of ETV:IDS For Potential Treatment Of Hunter Syndrome At MPS 2021


Benzinga | Jul 15, 2021 09:02AM EDT

Denali Therapeutics To Present Interim Data Phase 1/2 Study Of ETV:IDS For Potential Treatment Of Hunter Syndrome At MPS 2021

Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced its participation at MPS 2021, the 16th Annual International Symposium of MPS and Related Diseases, a research conference dedicated to the exchange of knowledge on mucopolysaccharidoses and related syndromes, taking place virtually July 23-25, 2021. Details related to Denali's oral presentation at MPS 2021 and a webinar hosted by Denali management following the presentation are provided below.



Oral Presentation at MPS 2021

Session Title: Late Breaking News / Oral Communications

Presentation Title: Interim 24-Week Results of Cohort A in a Ph I/II Study of Intravenous DNL310 (brain-penetrant enzyme replacement therapy) in MPS II

Date: Sunday, July 25th

Session Start Time: 16:05 p.m. CEST / 10:05 a.m. EDT / 7:05 a.m. PDT

Denali's presentation is the fifth presentation during the session and is slated to start at approximately 17:05 p.m. CEST / 11:05 a.m. EDT / 8:05 a.m. PDT.

Denali Webinar for Analysts and Investors

Following the presentation, Denali will host a webinar for analysts and investors to present the interim data from the Phase 1/2 study of DNL310. The webinar will begin at approximately 11:30 a.m. EDT / 8:30 a.m. PDT on Sunday, July 25, 2021, and will be available on Denali's corporate website on the Events page under the Investor section at https://www.denalitherapeutics.com/investors/events. An archived replay of the webinar will be available for at least 30 days following the event. Preregistration for the webinar can be accessed here.

Families interested in learning more about Denali's efforts related to the discovery and development of therapeutics for the potential treatment of Hunter syndrome are invited to visit EngageHunter.com, the Denali Hunter syndrome community engagement website.






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC